Compare
China SXT Pharmaceuticals, Inc. vs 60 Degrees Pharmaceuticals, Inc. vs Northwest Biotherapeutics Inc vs NRX Pharmaceuticals, Inc.
| Latest fiscal year | China SXT Pharmaceuticals, Inc. SXTC | 60 Degrees Pharmaceuticals, Inc. SXTP | Northwest Biotherapeutics Inc NWBO | NRX Pharmaceuticals, Inc. NRXP |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.14M | $1.01M | $1.38M | $1.45M |
| Revenue growth (YoY) | -34.6% | +65.5% | -0.3% | n/a |
| Gross margin | 21.9% | 22.3% | n/a | 65.1% (computed) |
| Operating margin | -625.9% | -771.6% | n/m | n/m |
| Net margin | -545.2% | -732.5% | n/m | n/m |
| Net income | -$6.21M | -$7.37M | -$60.16M | -$28.62M |
| EPS (Diluted) | -$9.13 | -$11.73 | -$0.04 | n/a |
| Operating cash flow | -$4.02M | -$6.85M | -$44.76M | -$14.11M |
| Free cash flow | n/a | -$6.99M | -$46.27M | n/a |
| Cash & equivalents | $28.18M | $1.51M | $3.04M | $7.80M |
| Total assets | $34.75M | $5.37M | $81.29M | $12.96M |
| Total liabilities | $5.05M | $1.99M | $128.86M | $28.89M |
| Shareholders' equity | $29.71M | $3.46M | -$60.28M | -$15.94M |
| Return on year-end equity | -20.9% | -212.7% | n/a | n/a |
| Shares outstanding | n/a | 1.16M | 1.56B | 31.73M |
Revenue, most recent five fiscal years
| Fiscal year | China SXT Pharmaceuticals, Inc. | 60 Degrees Pharmaceuticals, Inc. | Northwest Biotherapeutics Inc | NRX Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $1.14M Ended 2026-03-31 | $1.01M Ended 2025-12-31 | $1.38M Ended 2025-12-31 | $1.45M Ended 2025-12-31 |
| 1 year earlier | $1.74M Ended 2025-03-31 | $607.6K Ended 2024-12-31 | $1.38M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $1.93M Ended 2024-03-31 | $253.6K Ended 2023-12-31 | $1.93M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $1.97M Ended 2023-03-31 | $223.2K Ended 2022-12-31 | $1.68M Ended 2022-12-31 | n/a |
| 4 years earlier | $2.60M Ended 2022-03-31 | n/a | $1.00M Ended 2021-12-31 | n/a |